Zacks.com on MSN10h
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US
Pulmicort sales declined 4% to $138 million. Fasenra recorded sales of $436 million in the quarter, up 13% year over year, ...
Fiera Capital Corp Decreases Position in AstraZeneca PLC (NASDAQ:AZN)
Fiera Capital Corp trimmed its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.9% during the third quarter, according to the company in its most recent filing with the Securities and ...
Zacks.com on MSN6d
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings
Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...
lifesciencesweden.se8d
AZ gets approval for drug targeting rare disease –it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.
Daily12d
AstraZeneca Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...
Short Interest in AstraZeneca PLC (OTCMKTS:AZNCF) Declines By 10.0%
AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 37,100 shares ...
biopharma-reporter14d
AstraZeneca’s rare disease therapy Fasenra receives EU approval
The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...
Pharmaceutical Technology14d
EC approves AstraZeneca’s Fasenra for EGPA treatment
The European Commission (EC) has approved AstraZeneca ‘s Fasenra (benralizumab) as an add-on therapy for adults with ...
EuropaWire15d
AstraZeneca’s Fasenra Approved in EU for Treating Rare Vasculitis, Offering New Hope for EGPA Patients
(IN BRIEF) AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and severe ...
PharmiWeb15d
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...
PipelineReview.com15d
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids LONDON, UK I October 28, 2024 I ...
London South East15d
AstraZeneca pleased as EU approves Fasenra for treatment of EGPA
(Alliance News) - AstraZeneca PLC on Monday welcomed approval in the European Union of Fasenra for the treatment of eosinophilic granulomatosis with polyangiitis. EGPA is a rare, immune-mediated ...